Fcγ Receptor IIa
Fcγ receptor
antibodies
infants
severity
virus
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
09
2020
accepted:
19
11
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Most patients with respiratory syncytial virus (RSV) infection requiring hospitalization have no risk factors for severe disease. Genetic variation in the receptor for the Fc portion of IgG (FcγR) determines their affinity for IgG subclasses driving innate and adaptive antiviral immunity. We investigated the relationship between FcγRIIa-H131R polymorphism and RSV disease. Blood samples were collected from 182 infants ≤24-month-old (50 uninfected, 114 RSV-infected with moderate course and 18 suffering severe disease). FcγRIIa-H131R SNP genotypic frequencies (HH, HR, RR) and anti-RSV IgG1, IgG2 and IgG3 levels were studied. Genotypic frequencies for FcγRIIa-H131R SNP were comparable between uninfected and RSV-infected infants. In contrast, we found a significant higher frequency of HH genotype in severe RSV-infected children compared to moderate patients. Among severe group, HH infants presented more factors associated to severity than HR or RR patients did. Furthermore, compared to moderate RSV-infected infants, severe patients showed higher levels of anti-RSV IgG1 and IgG3. We found an association between an FcγRIIa (H131) polymorphism and severe RSV disease, which points towards a critical role for interactions between FcγRs and immune complexes in RSV pathogenesis. This genetic factor could also predict the worse outcome and identify those infants at risk during hospitalization.
Sections du résumé
Background
Most patients with respiratory syncytial virus (RSV) infection requiring hospitalization have no risk factors for severe disease. Genetic variation in the receptor for the Fc portion of IgG (FcγR) determines their affinity for IgG subclasses driving innate and adaptive antiviral immunity. We investigated the relationship between FcγRIIa-H131R polymorphism and RSV disease.
Methods
Blood samples were collected from 182 infants ≤24-month-old (50 uninfected, 114 RSV-infected with moderate course and 18 suffering severe disease). FcγRIIa-H131R SNP genotypic frequencies (HH, HR, RR) and anti-RSV IgG1, IgG2 and IgG3 levels were studied.
Results
Genotypic frequencies for FcγRIIa-H131R SNP were comparable between uninfected and RSV-infected infants. In contrast, we found a significant higher frequency of HH genotype in severe RSV-infected children compared to moderate patients. Among severe group, HH infants presented more factors associated to severity than HR or RR patients did. Furthermore, compared to moderate RSV-infected infants, severe patients showed higher levels of anti-RSV IgG1 and IgG3.
Conclusions
We found an association between an FcγRIIa (H131) polymorphism and severe RSV disease, which points towards a critical role for interactions between FcγRs and immune complexes in RSV pathogenesis. This genetic factor could also predict the worse outcome and identify those infants at risk during hospitalization.
Identifiants
pubmed: 33392111
doi: 10.3389/fcimb.2020.607348
pmc: PMC7775358
doi:
Substances chimiques
FCGR2A protein, human
0
Fc gamma receptor IIA
0
Receptors, IgG
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
607348Informations de copyright
Copyright © 2020 Holgado, Raiden, Sananez, Seery, De Lillo, Maldonado, Kamenetzky, Geffner and Arruvito.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 1997 Jan 18;349(9046):170-3
pubmed: 9111542
J Infect Dis. 1994 Oct;170(4):854-61
pubmed: 7930727
J Exp Med. 2002 Sep 16;196(6):859-65
pubmed: 12235218
Am J Respir Cell Mol Biol. 2020 Jul;63(1):133-136
pubmed: 32609012
Front Cell Infect Microbiol. 2019 Mar 29;9:75
pubmed: 30984626
Clin Biochem. 2011 Sep;44(13):1058-1061
pubmed: 21723269
Front Immunol. 2018 Nov 30;9:2814
pubmed: 30555482
Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9
pubmed: 25730467
Immunology. 2016 Jan;147(1):55-72
pubmed: 26451966
J Infect Dis. 2013 Feb 15;207(4):564-73
pubmed: 23204162
Tissue Antigens. 2005 Oct;66(4):291-6
pubmed: 16185324
J Clin Microbiol. 1989 Mar;27(3):589-92
pubmed: 2715331
Clin Infect Dis. 2000 Jan;30(1):25-8
pubmed: 10619728
Infect Genet Evol. 2016 Sep;43:213-21
pubmed: 27154330
Clin Microbiol Rev. 2005 Jul;18(3):541-55
pubmed: 16020689
Eur Respir J. 2012 Mar;39(3):604-10
pubmed: 21737555
J Infect Dis. 2019 Jan 29;219(4):514-516
pubmed: 30215722
Front Immunol. 2019 Mar 19;10:464
pubmed: 30941127
Annu Rev Immunol. 2017 Apr 26;35:501-532
pubmed: 28226227
J Infect Dis. 2017 Apr 1;215(7):1049-1058
pubmed: 28199704
Clin Immunol. 2006 Jan;118(1):20-3
pubmed: 16150646
J Immunol. 1991 Aug 15;147(4):1338-43
pubmed: 1831223
F1000Res. 2019 May 2;8:
pubmed: 31105933
Nat Immunol. 2014 Aug;15(8):707-16
pubmed: 25045879
Clin Infect Dis. 1998 Oct;27(4):746-50
pubmed: 9798027
Am J Trop Med Hyg. 2003 Dec;69(6):565-8
pubmed: 14740869
J Allergy Clin Immunol. 2009 Feb;123(2):398-403
pubmed: 19101023
Hum Immunol. 2015 Oct;76(10):717-23
pubmed: 26429310
PLoS Med. 2013 Nov;10(11):e1001549
pubmed: 24265599
Am J Respir Crit Care Med. 2017 Jan 1;195(1):96-103
pubmed: 27331632
Front Immunol. 2019 Mar 18;10:452
pubmed: 30936869
Vaccine. 1993 Nov;11(14):1415-23
pubmed: 7508665
J Immunol. 1992 Feb 1;148(3):695-701
pubmed: 1530954
J Virol. 2010 Mar;84(5):2374-83
pubmed: 20015982
Nat Med. 2012 Oct;18(10):1525-30
pubmed: 22961107
Am J Trop Med Hyg. 2010 Jun;82(6):1153-6
pubmed: 20519616
Immunobiology. 1995 Apr;192(5):297-320
pubmed: 7649565
Thorax. 2019 Oct;74(10):986-993
pubmed: 31383776
PLoS One. 2014 Feb 21;9(2):e89196
pubmed: 24586589
Clin Vaccine Immunol. 2013 Jun;20(6):900-6
pubmed: 23595505
Am J Respir Crit Care Med. 2014 Apr 1;189(7):865-8
pubmed: 24684360
Cell. 2015 Apr 9;161(2):387-403
pubmed: 25772697
J Virol. 2017 Oct 13;91(21):
pubmed: 28794038
Biomed Pharmacother. 2004 Jun;58(5):286-91
pubmed: 15194164
J Gen Virol. 1989 Jan;70 ( Pt 1):89-96
pubmed: 2732688
Annu Rev Immunol. 2001;19:275-90
pubmed: 11244038
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
Drugs Aging. 2005;22(7):577-87
pubmed: 16038573